Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerTowards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulationsPBPK modeling and simulation in drug research and developmentPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationA survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directionsApplication of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.The simcyp population based simulator: architecture, implementation, and quality assurance.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.The role of physiologically based pharmacokinetic modeling in regulatory review.PBPK as a tool in regulatory review.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature.Model-based clinical drug development in the past, present and future: a commentary.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.In silico ADME/T modelling for rational drug design.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative.Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug InteractionsPhysiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q26775949-34CC4CC3-875E-48FF-91CC-18C0CB32E6B2Q27020967-E6AB14BD-2A72-464E-B02A-3FFCF8CBF073Q28066513-BF0742DD-25A3-42EE-A69E-893F222A5A00Q28088352-8E2B3E8E-13DE-4A12-8A7A-33F6F0FEB44AQ30491777-55C2F778-19E4-4058-8706-A6D8B1DEBDAFQ34099766-5720F092-704C-40F8-8CFB-48AAE518F911Q34502721-7B9D7622-8EC6-455E-AD8C-078E9F1FECC6Q36910606-2101A304-F66A-4185-8C77-5489AC159A6EQ37121662-18F5EE1D-BFBA-48CD-A317-1671178FEE1BQ37978192-F407FD71-290B-4BEC-A81E-2486C95B246CQ37982653-C5EE173E-5728-4E6F-A37B-3958FE3DB06CQ37986722-830435FA-6F07-4D41-B319-8D6731DC884AQ38014312-9A86589F-56C2-43EA-82A8-E28493325A85Q38056878-AC1A8752-2C72-4A01-9DBE-247FB9305355Q38075057-A3FE8626-26B8-453B-857D-29088B77A1DCQ38087695-51DBB2E1-51EC-4BE1-AE18-5009BFFB95EFQ38110809-CF799664-AFA9-4DD4-B246-7B0E243A26B0Q38188035-04C86636-26CE-4020-82D4-0616BF0C425FQ38287050-5432673B-6BA3-469E-9E94-3A6E95A238C6Q38578341-08CF3D59-C91F-423C-8365-0A9155B3A832Q38844656-C34B883F-976C-4B78-923F-A821BF8D8C99Q38959281-72FAD77E-06EB-4AB8-AD49-604DABCF36FBQ39212609-AF908FCB-8847-474B-9BF9-9A50A27AB3B5Q39240124-04C87938-80E1-4B64-A57E-78A532CA1054Q39643626-8A3FB52B-1406-4C61-9B9D-6D38BCCB3868Q39645850-57443947-37E8-44D6-8A7F-3E75D4E8787BQ40072776-F4C4B8DF-AE43-4150-BA08-702E963DB590Q41819424-D5145B84-7392-4C82-853D-C9289A08CBF9Q42608257-F560F5AB-DC40-4084-A4B3-3F64A1987C3FQ45815953-3BC78643-61C9-4EE9-B4E2-39DA9539E365Q53233045-228B3197-D0D0-459F-B7A4-526E18186B9BQ53630136-2FABEB28-735E-4A20-BEFB-688AEB123072Q57684574-DE719529-051D-45D5-AFB9-37B057603916Q58073610-EFCA119A-6B0C-41DD-BE00-7A539DBC900C
P2860
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Evaluation of exposure change ...... netic modeling and simulation.
@en
Evaluation of exposure change ...... netic modeling and simulation.
@nl
type
label
Evaluation of exposure change ...... netic modeling and simulation.
@en
Evaluation of exposure change ...... netic modeling and simulation.
@nl
prefLabel
Evaluation of exposure change ...... netic modeling and simulation.
@en
Evaluation of exposure change ...... netic modeling and simulation.
@nl
P2093
P2860
P356
P1476
Evaluation of exposure change ...... netic modeling and simulation.
@en
P2093
Arthur J Atkinson
Darrell R Abernethy
Eva Gil Berglund
Jenny H Zheng
Joseph A Grillo
K Sandy Pang
Kellie S Reynolds
Lawrence J Lesko
Manuela de L T Vieira
P2860
P304
P356
10.1177/0091270011415528
P433
P577
2012-01-01T00:00:00Z